- Home
- PHAT
as of 12-09-2025 3:46pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 942.6M | IPO Year: | 2019 |
| Target Price: | $17.33 | AVG Volume (30 days): | 828.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $16.27 | Next Earning Date: | 10-30-2025 |
| Revenue: | $147,190,000 | Revenue Growth: | 460.30% |
| Revenue Growth (this year): | 218.59% | Revenue Growth (next year): | 84.38% |
AI-Powered PHAT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
Principal Accounting Officer
Avg Cost/Share
$13.51
Shares
524
Total Value
$7,079.24
Owned After
47,407
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | PHAT | Principal Accounting Officer | Nov 3, 2025 | Sell | $13.51 | 524 | $7,079.24 | 47,407 |
Compare PHAT vs Leading Stocks
See how PHAT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.